ADOPT model combined with structured health education alleviates the preoperative anxiety of patients undergoing preventive ileostomy
Development and validation of a comprehensive prevention-focused intervention package for problematic digital technology use among youth: a multi-site study protocol
Virtual reality-based inhibition training influences food-related responses: no additional effects of repetitive transcranial magnetic stimulation
Why we left the FDA: Six former officials share their stories
A year after U.S. DOGE Service cuts shook up the federal government, STAT’s FDA reporter Lizzy Lawrence has been speaking with former officials about their time at the agency. Two weeks ago, I hit the road with Lizzy to interview six of them about what drew them to the agency, the important work they did during their career there, and, ultimately, why they decided to leave during the second Trump administration.
In a special road-trip edition of STATus Report, Lizzy and I travel around the leafy suburbs of Washington to bring you first-person testimonies, including the former director of the FDA’s Center for Drug Evaluation and Research, Richard Pazdur; Sheryl Lard-Whiteford, a leader in the FDA’s biologics center; and Julie Tierney, who worked on Operation Warp Speed.
Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy
Interventions: Drug: Tadalafil 5 mg; Behavioral: Pelvic Floor Muscle Training (PFMT); Behavioral: Aerobic Exercise Program; Behavioral: Nutritional Recommendations; Behavioral: Psychological and Wellbeing Strategies; Behavioral: Standard Perioperative Care
Sponsors: Surgical Outcomes Research Centre (SOuRCe); Generic Health; National Health and Medical Research Council, Australia; Sydney Local Health District
Not yet recruiting
Macrophages Use Cell Volume Changes to Sense Danger and Amplify Inflammation
Macrophages are often described as the immune system’s first responders, but new work suggests they are also remarkably attuned to the physical state of their environment. A study published in the Journal of Cell Biology titled “Disruption of macrophage cell volume drives inflammatory responses and type I interferon signaling” reveals that shifts in cell volume act as a previously underappreciated danger signal—one that can rewire macrophage gene expression, heighten antiviral defenses, and intensify inflammatory responses.
The research, led by Jack Green, PhD, and colleagues at the University of Manchester, centers on the Volume‑Regulated Anion Channel (VRAC), a protein complex that helps cells maintain osmotic balance. When VRAC is missing, macrophages lose the ability to correct swelling under hypo‑osmotic stress. “Cell volume disruption induced type I interferon signaling through a DNA- and TBK1-dependent mechanism, but independent of cGAS and 2′3′-cGAMP transport,” the authors wrote. That loss of control, the team found, is far more consequential than a simple biophysical hiccup. It fundamentally alters how macrophages interpret threats.
Green noted that although earlier studies hinted at a connection between cell volume and inflammatory signaling, the underlying biology remained murky. “Despite the reported indications that cell volume and VRAC are involved in inflammatory signaling, the basic biological mechanisms of how the regulation of cell volume shapes inflammation were unknown,” he said. To probe that gap, the team examined VRAC‑deficient macrophages exposed to mild osmotic stress.
The swelling triggered broad reprogramming of gene expression, including the induction of antiviral and proinflammatory pathways. Many of the most strongly upregulated genes belonged to type I interferon signaling cascades or nucleic acid–sensing systems. First author James Cook frames the finding succinctly: “Together, these findings suggest that cell volume acts as an additional layer of danger sensing in macrophages that shapes and tunes the nature of immune responses to pathogens.”
That prediction held up in functional assays. When challenged with Influenza A virus, VRAC‑deficient macrophages mounted a more potent antiviral response than their wild‑type counterparts. The heightened sensitivity extended beyond viral infection. In mouse models of systemic hyperinflammation, animals lacking VRAC showed elevated levels of a key inflammatory mediator, indicating that dysregulated cell volume can exacerbate cytokine‑driven pathology in vivo.
Rather than responding solely to biochemical cues, these cells appear to fold physical perturbations—such as osmotic imbalance—into their danger‑sensing logic. Green argued that this perspective may help explain why inflammatory diseases can escalate unpredictably when tissue conditions shift. “Understanding disruptions in the tissue microenvironment leading to alterations in cell volume is therefore an important consideration in our understanding of inflammation and disease pathogenesis,” he concluded, adding that “future studies will reveal the potential for regulating VRAC‑dependent cell volume changes in macrophages in disease.”
The post Macrophages Use Cell Volume Changes to Sense Danger and Amplify Inflammation appeared first on GEN – Genetic Engineering and Biotechnology News.
Fraudulent citations, blamed on AI hallucinations, are becoming more common in research papers
Citations in academic papers are intended to ground research in the work that preceded it, over time creating something of a family tree explaining the roots of ideas, protocols, and studies.
But a growing number of these citations lead to dead ends. “Fabricated” citations that do not reference real papers are spreading in the literature, polluting the public record of science, a new study published Thursday in the Lancet shows. Tools using generative AI are likely to blame, say the Columbia University researchers who authored the paper.
Barriers and Facilitators in the Implementation of the Systematic Medical Appraisal, Referral, and Treatment (SMART) Mental Health Digital Intervention in Rural India: Mixed Methods Process Evaluation Study
From Sequence to Patient in Under 12 Months: A Case Study in Advancing Complex Cancer Immunotherapies
Joseph Shultz
Vice President of Technical Development and Manufacturing
Ottimo Pharma
Panelist
Joseph Shultz
Joseph Shultz is the vice president of technical development and manufacturing at Ottimo Pharma. His more than 30 years in the industry span development, manufacturing, quality, and technology development. He has held influential positions at Amgen, Novartis Pharma, the Battelle Memorial Institute, Evelo Biosciences, and Resilience. He initiated the technologies and led the strategies that resulted in next-generation biomanufacturing plants at both Amgen and Novartis.
Imroz Ghangas
Vice President of Commercial Sales
Asimov
Panelist
Imroz Ghangas
Imroz Ghangas and his team drive partnerships to advance Asimov’s genetic design platform and AI capabilities. With over 25 years in biotech, Imroz has evolved from process development scientist to commercial leader, bridging technical innovation with scalable solutions. His expertise spans bioprocess development and platform integration, with deep knowledge of biomanufacturing workflows from gene to drug product. He leverages his technical foundation to accelerate the adoption of next-generation bioprocessing technologies.
- Time:
Complex biologics such as bifunctional antibodies are opening new therapeutic possibilities in oncology, but these molecules present significant challenges for manufacturing teams. Non-standard architectures can often translate to low expression and difficult developability, making cell line development a critical bottleneck between a promising sequence and a viable clinical candidate.
In this GEN webinar, Joseph Shultz (vice president of technical development and manufacturing, Ottimo Pharma) and Imroz Ghangas (vice president of commercial sales, Asimov) discuss strategies for achieving high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year. Attendees will learn about the unique attributes of Ottimo’s molecule and how a specialist partnership with Asimov accelerated the program. The presenters will also introduce the CHO Edge System, which combines Asimov’s proprietary GS knock-out CHO host, hyperactive transposase, library of characterized genetic elements, and AI-driven genetic design tools to routinely deliver clonal titers of 8-12 g/L.
A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.
Produced with support from:
The post From Sequence to Patient in Under 12 Months: A Case Study in Advancing Complex Cancer Immunotherapies appeared first on GEN – Genetic Engineering and Biotechnology News.


